person · Reporting owner

Khattar Jack A.

Disclosed activity across 3 companies

Tapewire entity: 23273
SEC CIK: 0001539937

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COGNITION THERAPEUTICS INCCGTX · Entity 6792	Director	June 17, 2026	June 22, 2026
SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333	Director · President, CEO	August 12, 2026	August 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COGNITION THERAPEUTICS INC

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	73,500	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 25,000 · Balance 73,500 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 17, 2027 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.

SUPERNUS PHARMACEUTICALS, INC.

Report date August 12, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,258,351	Ending reported balance After 2026-08-12 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-12 · Exercise / conversion · Acquired 29,849 · Balance 1,270,993 Row 2 · 2026-08-12 · Tax withholding · Disposed 12,642 · Balance 1,258,351 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-08-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-08-12 · Exercise / conversion · Disposed 29,849 · Balance 0 F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Common StockSEC Table I · non-derivative	IndirectBy the KBT Trust	958,100	Reported balance Holding disclosure · report date 2026-08-12 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 958,100

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

F2: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

scPharmaceuticals Inc.

Report date October 07, 2025 · Filed October 07, 2025

Section 16 reporting ended · disclosed 2025-10-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-10-07 transaction · row 1 1 source row Row 1 · 2025-10-07 · Other · Disposed 5,000 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2035-06-03	Direct	Reported balance After 2025-10-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-10-07 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2034-06-11	Direct	Reported balance After 2025-10-07 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-10-07 · Disposition to issuer · Disposed 19,750 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2032-06-14	Direct	Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-07 · Disposition to issuer · Disposed 16,300 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2029-06-18	Direct	Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-10-07 · Disposition to issuer · Disposed 6,124 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of August 24, 2025 (the "Merger Agreement"), by and among the Issuer, MannKind Corporation ("Parent") and Seacoast Merger Sub, Inc., a direct wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's common stock ("Common Stock") on October 7, 2025. Tendering stockholders received per share consideration of $5.35 in cash, without interest, subject to any applicable withholding taxes, plus one non-tradable contingent value right ("CVR"), representing the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash,

F2: (Continued from footnote 1) without interest, subject to any applicable withholding taxes, upon the achievement of certain regulatory and net sales milestones on or prior to the applicable milestone outside dates. After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger", and the effective time of the Merger, the "Effective Time"), with the Issuer continuing as the surviving corporation in the Merger and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time and that had an exercise price per share that was less than $5.35, whether or not then vested or exercisable, was cancelled and converted into the right to receive (i) an amount in cash, without interest and subject to any applicable withholding taxes, equal to (A) the total number of shares subject to such Company Option immediately prior to such cancellation multiplied by (B) the excess, if any, of (x) $5.35 over (y) the exercise price payable per share underlying such Company Option and (ii) one CVR in respect of each share subject to such Company Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 14, 2022 Filed Jun 15, 2022 16:30 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	16,300	$0.00 Strike: $4.53	$0.00	Disclosure SEC source: 0000899243-22-022576 · doc4.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2032-06-14 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 14, 2023, or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
June 10, 2022 Filed Jun 13, 2022 20:46 UTC	COGNITION THERAPEUTICS INC CGTX · Entity 6792	GrantStock Option (right to buy) · Derivative	8,335	$0.00 Strike: $1.98	$0.00	Disclosure SEC source: 0001062993-22-014798 · form4.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,335 Underlying: Common Stock · 8,335 shares Expires 2032-06-10 F1 · derivative.exercise_date: The option vests on June 10, 2023, subject to the Reporting Person's continued service through the vesting date. Read SEC document
June 10, 2022 Filed Jun 23, 2022 20:07 UTC Amendment	COGNITION THERAPEUTICS INC CGTX · Entity 6792	GrantStock Option (Right to Buy) · Derivative	8,335	$0.00 Strike: $1.92	$0.00	Disclosure SEC source: 0001062993-22-015360 · form4a.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,335 Underlying: Common Stock · 8,335 shares Expires 2032-06-10 F1 · derivative.exercise_price: This amendment is being filed solely for the purpose of correcting a scrivener's error in this item. The correct exercise price is "$1.92" as shown herein, and not "$1.98" as was inadvertently entered in the original filing. F2 · derivative.exercise_date: The option vests on June 10, 2023, subject to the Reporting Person's continued service through the vesting date. Read SEC document
March 18, 2022 Filed Mar 24, 2022 01:21 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	10,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-037189 · tm229661-2_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,047,700 F1 · date: The Reporting Person was first notified of the completed transaction by the transfer agent on the filing date. F2 · price: The Reporting Person is filing this Form 4 to reflect the fact that 10,750 shares were transferred from the KBT Trust to the Reporting Person on March 18, 2022 without consideration and are now owned directly. Read SEC document
March 18, 2022 Filed Mar 24, 2022 01:21 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	10,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-22-037189 · tm229661-2_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 627,216 F1 · date: The Reporting Person was first notified of the completed transaction by the transfer agent on the filing date. F2 · price: The Reporting Person is filing this Form 4 to reflect the fact that 10,750 shares were transferred from the KBT Trust to the Reporting Person on March 18, 2022 without consideration and are now owned directly. Read SEC document
March 14, 2022 Filed Mar 17, 2022 21:10 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantCommon Stock	60,000	$0.00	$0.00	Disclosure SEC source: 0001104659-22-035103 · tm229661-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,466 F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 19, 2021. Read SEC document
March 14, 2022 Filed Jan 13, 2023 22:00 UTC Amendment	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionPerformance Share Unit · Derivative	40,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-003861 · tm233200-2_4aseq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 19, 2021, the Reporting Person was awarded Performance Shares Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document
March 14, 2022 Filed Jan 13, 2023 22:00 UTC Amendment	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001104659-23-003861 · tm233200-2_4aseq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576,466 F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 19, 2021. Read SEC document
March 14, 2022 Filed Jan 13, 2023 22:00 UTC Amendment	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	Exercise / conversionCommon Stock	40,000	$0.00	$0.00	Disclosure SEC source: 0001104659-23-003861 · tm233200-2_4aseq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 19, 2021. Read SEC document
February 22, 2022 Filed Feb 25, 2022 02:29 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $32.20	$0.00	Disclosure SEC source: 0001104659-22-026884 · tm227622-7_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-02-22 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document
December 03, 2021 Filed Dec 6, 2021 17:55 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	PurchaseCommon Stock	5,000	$3.91	$19,569.00	Disclosure SEC source: 0000899243-21-046980 · doc4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $3.90 to $3.923, inclusive. The reporting person undertakes to provide to scPharmaceuticals Inc., any security holder of scPharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (1) to this Form 4 Read SEC document
July 30, 2021 Filed Jul 30, 2021 20:32 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantCommon Stock	40,000	$0.00	$0.00	Disclosure SEC source: 0001104659-21-098285 · tm2123766-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,466 Read SEC document
July 30, 2021 Filed Jan 13, 2023 22:00 UTC Amendment	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantPerformance Share Unit · Derivative	40,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001104659-23-003860 · tm233200-1_4aseq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-19 F2 · derivative.exercise_date: On February 19, 2021, the Reporting Person was awarded Performance Shares Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document
June 08, 2021 Filed Jun 10, 2021 16:50 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	16,300	$0.00 Strike: $5.70	$0.00	Disclosure SEC source: 0000899243-21-022982 · doc4.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 16,300 shares Expires 2031-06-08 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 8, 2022, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
March 26, 2021 Filed Mar 30, 2021 22:23 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	10,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-044088 · tm2111424-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,058,450 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 10,000 shares were transferred from the KBT Trust to the Reporting Person on March 26, 2021 without consideration and are now owned directly. Read SEC document
March 26, 2021 Filed Mar 30, 2021 22:23 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	10,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-21-044088 · tm2111424-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,466 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 10,000 shares were transferred from the KBT Trust to the Reporting Person on March 26, 2021 without consideration and are now owned directly. Read SEC document
February 19, 2021 Filed Feb 23, 2021 23:49 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $29.61	$0.00	Disclosure SEC source: 0001104659-21-026931 · tm217706-6_4seq1.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-02-19 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2022. Read SEC document
July 27, 2020 Filed Jul 28, 2020 20:35 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantCommon Stock	15,625	$0.00	$0.00	Disclosure SEC source: 0001104659-20-087366 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,466 Read SEC document
July 10, 2020 Filed Jul 13, 2020 20:05 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantCommon Stock	15,625	$0.00	$0.00	Disclosure SEC source: 0001104659-20-083086 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 490,841 Read SEC document
June 09, 2020 Filed Jun 11, 2020 16:15 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	6,124	$0.00 Strike: $7.96	$0.00	Disclosure SEC source: 0000899243-20-016164 · doc4.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2030-06-09 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
March 23, 2020 Filed Mar 24, 2020 00:36 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	13,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-037450 · a4.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,068,450 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 13,000 shares were transferred from the KBT Trust to the Reporting Person on March 23, 2020 without consideration and are now owned directly. Read SEC document
March 23, 2020 Filed Mar 24, 2020 00:36 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	13,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-20-037450 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,216 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 13,000 shares were transferred from the KBT Trust to the Reporting Person on March 23, 2020 without consideration and are now owned directly. F1 · balance_after: The Reporting Person is filing this Form 4 to reflect the fact that 13,000 shares were transferred from the KBT Trust to the Reporting Person on March 23, 2020 without consideration and are now owned directly. Read SEC document
February 21, 2020 Filed Feb 25, 2020 22:24 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	281,250	$0.00 Strike: $23.99	$0.00	Disclosure SEC source: 0001104659-20-024849 · a4.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,250 Underlying: Common Stock · 281,250 shares Expires 2030-02-21 F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 21, 2021. Read SEC document
December 26, 2019 Filed Dec 27, 2019 21:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	1,100	$0.00	$0.00	Disclosure SEC source: 0001104659-19-076466 · a4.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 4,000 F3 · kind: This transaction involved a gift of securities by the Reporting Person to his son. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
December 26, 2019 Filed Dec 27, 2019 21:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	1,100	$0.00	$0.00	Disclosure SEC source: 0001104659-19-076466 · a4.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 461,841 F3 · kind: This transaction involved a gift of securities by the Reporting Person to his son. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
December 26, 2019 Filed Dec 27, 2019 21:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	1,100	$0.00	$0.00	Disclosure SEC source: 0001104659-19-076466 · a4.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,941 F2 · kind: This transaction involved a gift of securities by the Reporting Person to another daughter, who does not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document
December 26, 2019 Filed Dec 27, 2019 21:02 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	1,100	$0.00	$0.00	Disclosure SEC source: 0001104659-19-076466 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,041 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his daughter, who does not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document
August 23, 2019 Filed Aug 27, 2019 21:27 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	PurchaseCommon Stock	7,200	$26.39	$189,982.08	Disclosure SEC source: 0001104659-19-047536 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,141 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.0000 to $26.5100, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · balance_after: Includes an aggregate of 376 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document
June 18, 2019 Filed Jun 20, 2019 16:16 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	6,124	$0.00 Strike: $3.37	$0.00	Disclosure SEC source: 0000899243-19-017638 · doc4.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2029-06-18 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 18, 2020, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
March 20, 2019 Filed Mar 20, 2019 21:19 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	4,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-19-016356 · a4.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,081,450 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 4,500 shares were transferred from the KBT Trust to the Reporting Person on March 20, 2019 without consideration and are now owned directly. Read SEC document
March 20, 2019 Filed Mar 20, 2019 21:19 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	4,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-19-016356 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,565 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 4,500 shares were transferred from the KBT Trust to the Reporting Person on March 20, 2019 without consideration and are now owned directly. F1 · balance_after: The Reporting Person is filing this Form 4 to reflect the fact that 4,500 shares were transferred from the KBT Trust to the Reporting Person on March 20, 2019 without consideration and are now owned directly. Read SEC document
February 22, 2019 Filed Feb 27, 2019 00:28 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	300,000	$0.00 Strike: $36.75	$0.00	Disclosure SEC source: 0001104659-19-010802 · a4.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-02-22 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2020. Read SEC document
January 15, 2019 Filed Jan 17, 2019 23:04 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	400	$0.00	$0.00	Disclosure SEC source: 0001104659-19-002327 · a4.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 2,900 F4 · kind: This transaction involved a gift of securities by the Reporting Person to his son. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
January 15, 2019 Filed Jan 17, 2019 23:04 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	400	$0.00	$0.00	Disclosure SEC source: 0001104659-19-002327 · a4.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,065 F4 · kind: This transaction involved a gift of securities by the Reporting Person to his son. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
January 15, 2019 Filed Jan 17, 2019 23:04 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	400	$0.00	$0.00	Disclosure SEC source: 0001104659-19-002327 · a4.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,465 F3 · kind: This transaction involved a gift of securities by the Reporting Person to another daughter, who does not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document
January 15, 2019 Filed Jan 17, 2019 23:04 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	400	$0.00	$0.00	Disclosure SEC source: 0001104659-19-002327 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,865 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his daughter, who does not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. F2 · balance_after: Includes an aggregate of 521 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document
June 19, 2018 Filed Jun 21, 2018 18:39 UTC	scPharmaceuticals Inc. SCPH · Entity 74456	GrantStock Option (Right to Buy) · Derivative	6,124	$0.00 Strike: $5.53	$0.00	Disclosure SEC source: 0000899243-18-017632 · doc4.xml · derivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 Underlying: Common Stock · 6,124 shares Expires 2028-06-19 F1 · derivative.exercise_date: This stock option vests in full upon the earlier of (i) June 19, 2019, and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document
April 03, 2018 Filed Apr 4, 2018 21:12 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	3,800	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-022451 · a4.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,085,950 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 3,800 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2018 without consideration and are now owned directly. Read SEC document
April 03, 2018 Filed Apr 4, 2018 21:12 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	3,800	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-18-022451 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,744 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 3,800 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2018 without consideration and are now owned directly. F1 · balance_after: The Reporting Person is filing this Form 4 to reflect the fact that 3,800 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2018 without consideration and are now owned directly. Read SEC document
February 14, 2018 Filed Feb 16, 2018 21:58 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $39.40	$0.00	Disclosure SEC source: 0001104659-18-010411 · a4.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-02-14 F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 14, 2019. Read SEC document
December 22, 2017 Filed Dec 26, 2017 23:13 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	250	$0.00	$0.00	Disclosure SEC source: 0001104659-17-075074 · a4.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 2,500 F4 · kind: This transaction involved a gift of securities by the Reporting Person to his son. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
December 22, 2017 Filed Dec 26, 2017 23:13 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	250	$0.00	$0.00	Disclosure SEC source: 0001104659-17-075074 · a4.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,654 F4 · kind: This transaction involved a gift of securities by the Reporting Person to his son. The Reporting Person disclaims beneficial ownership of the shares held by his son, who shares the Reporting Person's household, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his son's shares for purposes of Section 16 or for any other purpose. Read SEC document
December 22, 2017 Filed Dec 26, 2017 23:13 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	250	$0.00	$0.00	Disclosure SEC source: 0001104659-17-075074 · a4.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,904 F3 · kind: This transaction involved a gift of securities by the Reporting Person to another daughter, who does not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. Read SEC document
December 22, 2017 Filed Dec 26, 2017 23:13 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GiftCommon Stock	250	$0.00	$0.00	Disclosure SEC source: 0001104659-17-075074 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,154 F1 · kind: This transaction involved a gift of securities by the Reporting Person to his daughter, who does not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose. F2 · balance_after: Includes an aggregate of 495 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document
April 03, 2017 Filed Apr 4, 2017 20:57 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	4,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-17-021402 · a4.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By the KBT Trust Disclosed balance after: 1,089,750 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 4,250 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2017 without consideration and are now owned directly. Read SEC document
April 03, 2017 Filed Apr 4, 2017 20:57 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	OtherCommon Stock	4,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-17-021402 · a4.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,909 F1 · price: The Reporting Person is filing this Form 4 to reflect the fact that 4,250 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2017 without consideration and are now owned directly. F1 · balance_after: The Reporting Person is filing this Form 4 to reflect the fact that 4,250 shares were transferred from the KBT Trust to the Reporting Person on April 3, 2017 without consideration and are now owned directly. Read SEC document
February 24, 2017 Filed Feb 28, 2017 02:57 UTC	SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333	GrantEmployee Stock Option (Right to Buy) · Derivative	325,000	$0.00 Strike: $25.30	$0.00	Disclosure SEC source: 0001104659-17-012174 · a4.xml · derivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2027-02-24 F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.